Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases

A compound according to Formula 2:

• wherein;
• X is selected from S or S═O;
• Q is selected from CH2 or CO;
• n is selected from 0, 1, 2 or 3;
• R1, R2, R3 and R4, are selected from hydrogen, halogen, F, Br, Cl, CH3, CF3, OCH3, COCH3, CN, C(O)R8 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl;
• R6 is selected from hydrogen, CH3, CF3, OCH3, COCH3, CN, C(O)R8, optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3 -C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl,
• Wherein R8 is optionally selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, and
• pharmaceutically acceptable salts and enantiomers thereof.

A compound according to Formula 3:

• wherein;
• X is selected from S or S═O;
• Q is selected from CH2 or CO;
• n is selected from 0, 1, 2 or 3;
• R1, R2, R3 and R4, are selected from hydrogen, halogen, F, Br, Cl, CH3, CF3, OCH3, COCH3, CN, C(O)R8 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl;
• R6 is selected from hydrogen, CH3, CF3, OCH3, COCH3, CN, C(O)R8 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8 alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl,
• R7 is selected from hydrogen, CH3, CF3, OCH3, COCH3, CN, C(O)R8 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl,
• wherein R8 is optionally selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8alkoxyC1-C8alkyl, optionally substituted C1-C8alkylaminoC1-C8alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl;
• and
• pharmaceutically acceptable salts and enantiomers thereof.